How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SP

NASDAQ:SPRO
Get a brief AI stock analysisSaves ~ 15 minutes of your time

SP

Spero Therapeutics IncNASDAQ SPRO Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is SPRO undervalued compared to its fair value?

The fair value of SPRO stock is hidden USD. Relative to the market price of 1.38 USD Spero Therapeutics Inc is hidden.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial in...[More about valuation]

Spero Therapeutics Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.075 $B

Price:

1.38 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.237

FINANCIALS

Spero Therapeutics financial for reporting period

Income Statement

0.0093 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.014 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.013 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0093 B 100%
-0.014 B -151%
-0.013 B -137%

Balance Sheet

0.17 B
0.096 B

Financial Position Analysis

Assets

0.17 B
Current Assets
0.14 B
Total non-current assets
0.028 B

Total current liabilities
0.042 B
Total non-current liabilities
0.03 B

Cash Flow Statement

0.0059 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.0059 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Spero Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

30 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
116 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
17 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Spero Rating

Is SPRO attractive for investment based on fundamental analysis?

SPRO stock rating is hidden. Spero Therapeutics is a hidden by Eyestock methodology.

Get SPRO Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

21

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

3.793

Debt / Equity ratio:

ROE:

30

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

SPRO analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for SPRO to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Spero Therapeutics Inc dividends

SPRO dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About SPRO stock

About the company Spero Therapeutics Inc

Market cap $B

0.075

Dividend yield

Shares outstanding

51.7761 B

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed to be the first oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the first oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV) administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections within the hospital.

SPRO profile

  • Ticker

    SPRO

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    02 November 2017

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    41

  • City

    Cambridge

  • Address

    675 Massachusetts Ave Ste 14

  • Cusip

    84833T103

Frequently Asked Questions

What sector does Spero operate in?

Spero operates in Healthсare sector

What is market cap of Spero?

Market cap of Spero is 0.075 USD as of 24 Jul 2024

What is market price of one SPRO stock?

Market price of one SPRO stock is 1.38 USD as of 24 Jul 2024

What is Spero revenue?

According to the recent report Spero revenue is 9.267

What is Spero net income?

According to the recent report Spero net icnome is -12.669

What is Spero net income growh rate?

Net income growth rate of Spero is 6